Literature DB >> 11801705

18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.

Szabolcs Szakáll1, Olga Esik, Gábor Bajzik, Imre Repa, Gabriella Dabasi, István Sinkovics, Péter Agoston, Lajos Trón.   

Abstract

UNLABELLED: Postsurgically elevated or increasing serum calcitonin levels strongly suggest the presence of residual or recurrent medullary thyroid carcinoma (MTC). Several imaging modalities (sonography, MRI, CT, scintigraphy with different types of radiolabeled ligands, etc.) are routinely used in an attempt to localize tumorous tissue, but such efforts often fail. In the search for a more reliable method, 18F-FDG PET was applied to detect tumor tissue of residual or recurrent MTC.
METHODS: Forty patients with a postoperatively elevated plasma calcitonin level were included. These patients underwent routine diagnostic imaging procedures (CT, MRI, and 131I-metaiodobenzylguanidine [MIBG] whole-body planar scintigraphy or SPECT) and 18F-FDG PET examinations. Two independent experts visually analyzed the images provided by each method to detect pathologic lesions. Lymph nodes of > or = 1 cm in short diameter that were detected by radiologic methods were considered to be pathologic. 18F-FDG accumulation with a sharp contour reported by both independent observers was similarly regarded as pathologic.
RESULTS: PET detected 270 foci with a high tracer accumulation, whereas only 116 lesions were detected by MRI and 141 by CT. The numbers of such foci determined by PET, MRI, and CT were 98, 34, and 34, respectively, in the neck; 25, 5, and 6, respectively, in the supraclavicular regions; and 117, 35, and 39, respectively, in the mediastinum. 131I-MIBG scintigraphy findings were positive for only 3 patients.
CONCLUSION: For MTC patients with a postoperatively elevated plasma tumor marker level, PET was more sensitive and superior in localizing tumorous lymph node involvement than were the other imaging modalities, especially in the cervical, supraclavicular, and mediastinal lymphatic regions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801705

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  35 in total

1.  Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.

Authors:  Marc-André Fortin; Alexei V Salnikov; Marika Nestor; Nils-Erik Heldin; Kristofer Rubin; Hans Lundqvist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-03       Impact factor: 9.236

2.  The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma.

Authors:  Trond Velde Bogsrud; Dimitrios Karantanis; Mark A Nathan; Brian P Mullan; Gregory A Wiseman; Jan L Kasperbauer; Carl C Reading; Trine Björo; Ian D Hay; Val J Lowe
Journal:  Mol Imaging Biol       Date:  2009-12-01       Impact factor: 3.488

3.  Diagnostic performance of CT in detection of metastatic cervical lymph nodes in patients with thyroid cancer: a systematic review and meta-analysis.

Authors:  Se Jin Cho; Chong Hyun Suh; Jung Hwan Baek; Sae Rom Chung; Young Jun Choi; Jeong Hyun Lee
Journal:  Eur Radiol       Date:  2019-02-26       Impact factor: 5.315

Review 4.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

5.  Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.

Authors:  Heejin Kim; Kyung Jin Na; Jae Hyuk Choi; Byeong-Cheol Ahn; Dongbin Ahn; Jin Ho Sohn
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-14       Impact factor: 2.503

6.  Medullary carcinoma of the thyroid with axillary metastasis: a case report.

Authors:  Murat Ozdemir; Ozer Makay; Ilgin Simsir; Yeşim Ertan; Gokhan Icoz; Füsun Saygili; Mahir Akyildiz
Journal:  Int Surg       Date:  2015-03

7.  Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma.

Authors:  Martin Gotthardt; Martin P Béhé; Daniela Beuter; Anke Battmann; Artur Bauhofer; Tino Schurrat; Meike Schipper; Halina Pollum; Wim J G Oyen; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-11       Impact factor: 9.236

Review 8.  Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer.

Authors:  Ioannis Ilias; Chaitanya Divgi; Karel Pacak
Journal:  Semin Nucl Med       Date:  2011-09       Impact factor: 4.446

9.  Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT.

Authors:  Andrei Iagaru; Rinat Masamed; Peter A Singer; Peter S Conti
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

10.  Markov model-based estimation of individual survival probability for medullary thyroid cancer patients.

Authors:  Olga Esik; Gábor Tusnády; Lajos Trón; András Boér; Zoltán Szentirmay; István Szabolcs; Károly Rácz; Erzsébet Lengyel; Judit Székely; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.